Roche Wins Priority FDA Review for Lung Cancer DrugBy
FDA to reach decision on alectinib before March 4, 2016
Drug may get nod for patients who resist standard chemotherapy
Roche Holding AG’s experimental drug alectinib will be fast-tracked by U.S. regulators to treat a form of aggressive lung cancer that has spread.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.